Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis - 24/04/13
, Amy M. Reese, MD b, John P. Trafeli, MD c
Reprint requests: Julia M. Kwan, MD; Naval Medical Center San Diego, c/o Susana Hazelden, Clinical Investigation Department; 34800 Bob Wilson Dr, San Diego, CA 92134.Abstract |
Efalizumab, a humanized anti-CD11a monoclonal antibody, has been shown to treat plaque psoriasis. A known association between this drug and autoimmune thrombocytopenia has already been established. More recently publicized, however, is efalizumab’s ability to affect another cell line—that of the erythrocyte—and cause an autoimmune hemolytic anemia that typically occurs 4 to 6 months after initiating therapy. In this article, we report the case of a patient who developed autoimmune hemolytic anemia after 8 months of successful treatment with efalizumab. His delayed presentation suggests that monitoring of blood cell counts longer than 6 months may be warranted.
Le texte complet de cet article est disponible en PDF.Abbreviations used : DAT, IAT, MTS
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government. |
Vol 58 - N° 6
P. 1053-1055 - juin 2008 Retour au numéro
Article précédent
- Retronychia: Report of two cases
- Maurice J. Dahdah, Abdul Ghani Kibbi, Samer Ghosn
- Pustulosis acuta generalisata with joint involvement in an HLA-A2– and HLA-B35–positive patient
- Mittra Eren, Mario Fabri, Thomas Krieg, Sabine A. Eming
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?